-- RBT-101, Radiant's lead oncology program and 4-1BB agonist, demonstrated robust, durable and complete tumor regression without liver toxicity in MC38 colorectal mouse tumor model -- Poster ...
By Daniella Parra Radiant Biotherapeutics presented data from their advancing a breakthrough antibody approach, the Multabody ...
1d
Radiant Biotherapeutics to Present New Data from Lead Oncology Program at SITC 2025 Annual Meeting
Radiant Biotherapeutics, a biotechnology company committed to advancing a breakthrough antibody approach, the Multabody™, for a broad range of therapeutic areas, including cancer and infectious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback